Align Misses Invisalign Volume View, Guides Below Street

Align Technology beat second-quarter earnings estimates but fell short on Invisalign case volume and issued a third-quarter outlook that missed analyst expectations.

The company reported adjusted earnings of $2.71 a share on revenue of $1.05 billion for the three months ended June 30. Analysts had forecast $2.62 a share on $1.04 billion, according to consensus compiled by Bloomberg. Invisalign case volume totaled 618,400, below the 621,000 Wall Street expected.

Teen and doctor-directed cases dropped 12.6% from a year earlier. Asia Pacific volume was flat. The Americas, Align's largest region, posted 3.1% year-over-year growth, driven by orthodontist adoption.

Revenue from systems and services, which includes scanners and software, rose 5.4% to $178.8 million. Gross margin narrowed to 69.2% from 70.2% a year ago, reflecting higher scanner costs and product mix.

Guidance disappoints

For the third quarter, Align forecast Invisalign case volume of 590,000 to 610,000, well below the 622,000 analysts were expecting. The weak outlook overshadowed the second-quarter beat and sent the stock lower in after-hours trading.

CEO Joe Hogan said on the call that the company is investing in marketing and sales to drive adoption of the new Invisalign Palatal Expander, a device approved by the Food and Drug Administration in the first quarter. The expander treats crossbites and crowding without surgery and is a key growth driver for 2027, Hogan said.

"We are still in the early stages of the expander launch. We expect it to be a multiyear growth story," Hogan said.

Cash flow and buybacks

Align generated $178.7 million in operating cash flow during the quarter, down from $186.6 million a year earlier. The company spent $101.2 million on share repurchases and dividends, leaving $759.4 million in cash and investments on the balance sheet.

AlphaScala sentiment

Align Technology carries an Alpha Score of 58 out of 100, a "Moderate" rating. The stock trades at 23 times forward earnings, below its five-year average of 32, suggesting value. The weak guidance raises questions about near-term demand.

The second-quarter print had a pattern familiar to Align watchers: beat on earnings, miss on volume, guide down. The stock has fallen 18% this year through Tuesday's close, versus the S&P 500's 8% gain. Hogan's bet on the Palatal Expander is the most concrete catalyst on the horizon, though it will take quarters to show up in the numbers.